Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies

Project description

Novel nanocomposites for precision cancer therapy

Cancer treatments face limitations due to inadequate tumour targeting, inherent toxicity and resistance mechanisms associated with hypoxic tumour microenvironments. Nano-metal organic frameworks, characterised by porous nanostructure and tunable chemical properties, present a promising platform for overcoming these limitations. With the support of the Marie Skłodowska-Curie Actions programme, the Photo-bioMOF project aims to engineer multifunctional nanocomposites that combine four treatment modalities: photothermal therapy, photodynamic therapy, radiotherapy sensitisation and light-triggered drug release. The efficacy of this platform for precise and synergistic therapy will be validated in lung cancer cell models, patient-derived organoids and vascularised tumour models. The underlying design principles can be adapted to other cancer types and applications in environmental sensing and photocatalysis.

Objective

Cancer remains one of the most pressing global health challenges, with current therapies often limited by toxicity, hypoxia, and lack of spatial precision. Photo-bioMOF addresses these barriers by pioneering a new generation of multifunctional nanoMOFs for fully integrated multimodal cancer therapy. The project introduces an unprecedented design: direct incorporation of Au(III) into MOF linkers, enabling the in situ formation of photoactive AuNPs within the tumor microenvironment. In parallel, introducing a heavy metal (e.g. Hf4+) into the clusters lowers the HOCO–LUCO band gap, amplifying light absorption, boosting ROS generation, and enhancing radiosensitivity under irradiation. By unifying these 2 mechanisms within a single framework, Photo-bioMOF will create a platform where photothermal, photodynamic, and radiotherapeutic functions converge, while also enabling irradiation-triggered chemotherapy release—achieving, for the first time, a fully integrated 4-in-1 nanomedicine. Beyond chemical innovation, the project establishes proof of concept through a staged validation pipeline: in vitro studies on pulmonary cells (host), ex vivo testing in patient-derived 3D lung organoids (secondment), and in ovo evaluation using vascularized tumor models (non-academic placement). This workflow ensures robust assessment of efficacy, biodistribution, and safety, while consolidating the fellow’s expertise in MOF design and providing outstanding training in nanotechnology, biological validation, and translational nanomedicine—strengthening independence and leadership potential. By initially targeting lung cancer the project addresses an unmet medical need, while its design principles are adaptable to other cancers or diseases (e.g. infections). In parallel, the structural and photochemical versatility of nanoMOFs enables applications in energy and environment (e.g. photocatalysis, decontamination, sensing), positioning Photo-bioMOF at the frontier of translational nanoscience.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

Fundacion IMDEA Energia
Net EU contribution
€ 262 393,20
Address
AVENIDA RAMON DE LA SAGRA 3
28935 Mostoles Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
No data

Partners (2)